Novel Primate-Specific Genes, RMEL 1, 2 and 3, with Highly Restricted Expression in Melanoma, Assessed by New Data Mining Tool by Sousa, Josane F. et al.
Novel Primate-Specific Genes, RMEL 1, 2 and 3, with
Highly Restricted Expression in Melanoma, Assessed by
New Data Mining Tool
Josane F. Sousa
1., Raul Torrieri
1., Rodrigo R. Silva
1, Cristiano G. Pereira
1, Valeria Valente
2, Erico
Torrieri
1, Kamila C. Peronni
1, Waleska Martins
3, Nair Muto
3, Guilherme Francisco
4, Carla Abdo Brohem
5,
Carlos G. Carlotti Jr.
2, Silvya S. Maria-Engler
5, Roger Chammas
4, Enilza M. Espreafico
1*
1Departamento de Biologia Celular e Molecular e Bioagentes Patoge ˆnicos, Faculdade de Medicina de Ribeira ˜o Preto, Universidade de Sa ˜o Paulo, Ribeira ˜o Preto, Sa ˜o
Paulo, Brazil, 2Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeira ˜o Preto, Universidade de Sa ˜o Paulo, Ribeira ˜o Preto, Sa ˜o Paulo, Brazil, 3Clinical
Staff, Molecular Biology Group, Pathology Division, AC Camargo Hospital Melanoma Group, Sa ˜o Paulo, Sa ˜o Paulo, Brazil, 4Departamento de Radiologia e Instituto do
Ca ˆncer do Estado de Sa ˜o Paulo, Faculdade de Medicina, Universidade de Sa ˜o Paulo, Sa ˜o Paulo, Sa ˜o Paulo, Brazil, 5Departamento de Ana ´lises Clı ´nicas e Toxicolo ´gicas,
Faculdade de Cie ˆncias Farmace ˆuticas, Universidade de Sa ˜o Paulo, Sa ˜o Paulo, Sa ˜o Paulo, Brazil
Abstract
Melanoma is a highly aggressive and therapy resistant tumor for which the identification of specific markers and therapeutic
targets is highly desirable. We describe here the development and use of a bioinformatic pipeline tool, made publicly
available under the name of EST2TSE, for the in silico detection of candidate genes with tissue-specific expression. Using this
tool we mined the human EST (Expressed Sequence Tag) database for sequences derived exclusively from melanoma. We
found 29 UniGene clusters of multiple ESTs with the potential to predict novel genes with melanoma-specific expression.
Using a diverse panel of human tissues and cell lines, we validated the expression of a subset of three previously
uncharacterized genes (clusters Hs.295012, Hs.518391, and Hs.559350) to be highly restricted to melanoma/melanocytes
and named them RMEL1, 2 and 3, respectively. Expression analysis in nevi, primary melanomas, and metastatic melanomas
revealed RMEL1 as a novel melanocytic lineage-specific gene up-regulated during melanoma development. RMEL2
expression was restricted to melanoma tissues and glioblastoma. RMEL3 showed strong up-regulation in nevi and was lost
in metastatic tumors. Interestingly, we found correlations of RMEL2 and RMEL3 expression with improved patient outcome,
suggesting tumor and/or metastasis suppressor functions for these genes. The three genes are composed of multiple exons
and map to 2q12.2, 1q25.3, and 5q11.2, respectively. They are well conserved throughout primates, but not other genomes,
and were predicted as having no coding potential, although primate-conserved and human-specific short ORFs could be
found. Hairpin RNA secondary structures were also predicted. Concluding, this work offers new melanoma-specific genes for
future validation as prognostic markers or as targets for the development of therapeutic strategies to treat melanoma.
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Introduction
Melanoma is an aggressive tumor marked by high metastatic
potential and drug resistance [1,2]. In the last decades its incidence
worldwide has increased considerably [3]. Thus, great interest
exists in the identification of genes of melanoma-specific
expression that may lead to new markers to monitor the disease
status or to new therapeutic targets.
Tissue-restricted expression is a desirable property for
candidate genes as therapeutic targets in cancer, since their
function could be inhibited without damaging normal tissues,
their promoters could be used to enhance expression of cell
death-inducing proteins in tumor cells, and tumor-specific
proteins could serve as targets for immunotherapy or site-specific
delivery of antitumor agents.
Besides the annotation of human genes, expressed sequence tags
(ESTs) have also been used for the identification of tissue-specific
genes [4,5], including genes differentially expressed in normal and
tumor tissues [6], and those encoding cancer/testis tumor
antigens, characterized by their predominant expression in germ
cells, trophoblast cells, and tumor tissues [7]. More recently, EST
data and its associated UniGene information were used to create a
database of genes preferentially expressed in 30 tissues [8,9].
In this work, we report the identification of a group of UniGene
clusters containing multiple ESTs derived exclusively from
melanoma. We also describe the scheme of the in silico pipeline
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database and make the software generated publicly available.
Moreover, we show experimental validation of an unprecedent-
edly highly restricted melanoma expression profile for a subset of
three genes besides some clues to their functions according to
correlations between gene expression and clinical data. Finally,
based on sequence analysis, we present the exon/intron
organization of these genes and putative gene products.
Results
Identification of 29 UniGene clusters represented by
expressed sequences exclusively detected in melanoma
libraries
With the aim of identifying genes with melanoma restricted
expression we developed a simple in silico pipeline that then was
implemented as a new online tool, EST2TSE (Table S1). The tool
allows the mining of all available human EST data in a search for
candidate genes with tissue restricted expression. Although our
tool is simpler than tools of similar function, such as Gene Library
Summarizer (GLS) [10] from the Cancer Genome Anatomy
Project-CGAP, UniGene Digital Differential Display – DDD [11]
and the Tissue-specific Gene Expression and Regulation-TiGER
database [12], it allows a more straightforward search for specific
terms, for example, some tumor types or subtypes, since we can
use as keyword any of the terms associated to the cell or tissue type
in the GenBank reports (Table S1). Actually, the TiGER database
does not allow a search for melanoma-specific genes, since it
presents a pre-defined list of tissue names that does not include
melanoma, instead, only offers the term ‘‘skin’’. Similar to GLS
from CGAP, EST2TSE detects candidate genes with tissue- or
condition-restricted expression (unique genes, represented by
sequences found only in the selected tissue/condition), in contrast
to UniGene Digital Diferential Display – DDD and TiGER that
detect genes with enriched expression.
Using this pipeline tool we identified 215 UniGene clusters
composed of ESTs detected only in melanoma libraries. Of these,
177 clusters were composed of a single EST per cluster and thus
were removed to minimize the chance of selecting artifacts or
genes with very low expression. The other 38 clusters with multiple
ESTs or complete cDNA sequences underwent additional analysis
by BLAST and BLAT alignments, which eliminated nine
additional clusters that matched cDNA sequences from tissues
other than melanoma. Six clusters containing ESTs from other
tumor types (Hs.382776, Hs.407538, Hs.586239, Hs.637822,
Hs.650135) or from testis (Hs.570414), besides those from
melanoma libraries, were included, as they might represent tumor
antigens. As summarized in Table S2, of the 29 clusters selected,
19 have coding potential based on the occurrence of deduced
amino acid sequences in GenBank or as predicted by the CPC
software [13], and most have ORFs encoding less than 200 aa.
Among the predicted proteins there are 5 putative nucleic acid-
binding proteins, a tubulin annotated as tubulin beta4Q, and 13
proteins with no characterized domains. Among the predicted
nucleic acid-binding proteins there is a member (SSX-5) of a
known family of cancer-testis antigens. Also, one ORF
(Hs.570414) encodes a transmembrane protein as predicted by
Phobius [14]. The clusters Hs.551051 and Hs.617329 are likely to
represent the same gene, which is one of the many versions of the
human LINE-1 retrotransposon. Although the cDNA sequences
from the two clusters are polyadenylated and do not overlap, they
align very closely to each other on the human chromosome 4
p15.33 and, according to Blastp results, the deduced ORFs from
each one match different regions of the ORF2 protein of LINE-1
retrotransposon element. Interestingly, we identified two other
genes (Hs.570688 and Hs.385543) also matching domains of
LINE-1 ORF2.
The putative promoter region of 22 genes had putative elements
for 4 transcription factors, namely C/EBPalpha, NF1, Oct-1, and
SP-1. Most had putative binding sites for another 11 transcription
factors (Table S3).
Experimental validation confirms highly restricted
expression of three novel genes in melanoma or
melanocyte lineage
For validation experiments we selected UniGene clusters
composed of three or more GenBank sequences (Tables S2 and
S4), excluding Hs.551051 and Hs.617329 that required further
analysis to clarify whether they represent a single gene. Primer
efficiency tests revealed six of nine genes with very low expression
levels (Ct.34). Thus, we focused on the other three genes
(Hs.295012, Hs.518390, Hs.559350) showing more consistent and
reliable expression levels. As shown in Figure 1, expression analysis
in a diverse panel of human cell lines and tissues confirmed highly
restricted expression of these three genes in melanocyte/
melanoma cells, so we named them as RMEL1 (Hs.295012),
RMEL2 (Hs.518391), and RMEL3 (Hs.559350). Except for very
low levels found in a single glioblastoma sample (GBM-2), RMEL1
mRNA expression was detected only in samples from melanocytic
origin, including the two primary melanocyte cultures and 14 of 19
melanoma cell lines, confirming its highly restricted expression in
melanocytic cells (Figure 1A). RMEL2 mRNA expression was
detected in 13 out of 19 melanoma cell lines, and no expression
was detected in melanocytes, nor in 29 samples from other cell and
tissue types (Figure 1B). However, despite the lack of expression in
normal glia, high levels were detected in one (GMB-3) out of three
glioblastoma samples (Figure 1B), suggesting that this gene, and
perhaps RMEL1 as well, are part of a common tumorigenic tract
involved in these two types of neuroectoderm-derived tumors.
RMEL3 mRNA expression was detected in 13 out of 19 melanoma
cell lines and in low levels in two normal bladder samples and one
prostate tumor (Figure 1C). No expression was detected in
melanocytes nor in 28 samples from other types of cells and
tissues. Interestingly, there was a positive correlation between the
expression of these three genes and the occurrence of oncogenic
mutation of BRAF (Figure 1A–C).
We next analyzed the expression profile of these genes in a
panel of nevi, primary, and metastatic melanoma tissues, including
a sample from primary cultured keratinocytes as control (Figure 2).
Real-time RT-PCR results showed lack of mRNA expression in
keratinocytes, while significant differential expression was detected
for the three genes in nevi and melanomas of both stages. Both
RMEL1 and RMEL2 showed up-regulation in about 45 to 50% of
the tumor samples. On the other hand, RMEL3 exhibited the
inverse expression pattern, marked by relatively high levels in nevi
and progressive loss during melanoma progression, as revealed by
its loss in 31% of the primary tumors and in 88% of the metastatic
tumors (Figure 2A–C).
Correlations of gene expression and clinical data provide
insights into the role of RMEL genes in tumor
progression
We performed a small scale study to correlate RMEL
expression levels with clinical and histopathological features.
Although we did not have data for all patients included in the
expression study, we did so for a limited number of patients,
allowing us to extract some correlations that provide initial clues of
Novel Melanoma-Specific Genes
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divided the patients into two groups according to the expression
levels, smaller or equal and greater than the maximal expression
observed in nevi, for RMEL1, and detected (D) and non-detected
(ND), for RMEL2 and RMEL3. Expression levels of RMEL1
showed correlation with skin color (15 of 16 patients with
expression of RMEL1 lower/equal than nevi were white, while
only 9 of 14 were white in the group with high expression,
p=0.038) and tumor thickness (3/7 patients with low or lack of
expression presented Clark levels IV/V, the other 4/7 were Clark
I/II, in contrast 8/8 patients with high expression had Clark levels
IV/V, p=0.012). However, there was no correlation of RMEL1
expression with other relevant features of tumor progression or
patient outcome (Figure 3A). RMEL2 expression correlated
significantly (p=0.026) with lymph node status, such that 73%
(11/15) of the patients with detectable expression in the tumor
showed the presence of tumor cells in lymph nodes against 33%
(5/15) in the group lacking expression. Interestingly, mortality due
to cancer in lymph node positive patients was 67% in the group
with detectable expression of RMEL2 and 100% in the group
lacking expression. Moreover, all lymph node-negative patients
with expression of the gene lived (4/4) without developing disease
while regardless of being lymph node negative most patients
lacking expression of the gene died (83%, 5/6) due to cancer or
developed the disease (1/6) over equivalent periods of follow up.
Overall mortality in the population analyzed was around 53% in
the lymph node-positive group and 33% in lymph node negative.
Cells from tumors with preserved expression of RMEL2 showed
either spindle (4/9) or epithelioid (5/9) shapes while those from
tumors lacking expression were all epithelioid (6/6), p=0.025.
Additionally, RMEL2 expression showed a tendency of correlation
with improved survival rate (Figure 3B). For RMEL3, we observed
a significant (p=0.002) inverse correlation of gene expression and
tumor progression, so that the majority (13/19, 68%) of the
patients lacking RMEL3 expression in their tumor sample
presented with metastasis, most of them (9/13, 77%) in an
aggressive (visceral) stage of the disease, whereas in contrast only a
minority (3/13, 23%) of the patients with preserved RMEL3
expression were diagnosed with metastasis. Also, the only two
metastatic samples with preserved RMEL3 expression were
derived from less advanced, lymph nodal or cutaneous metastasis
while all advanced metastases lacked expression (Figure 2C).
Compatible with a protective role for RMEL3, we observed
correlation of expression with the absence of lymph vascular
invasion in the primary tumor site (10/11 patients), while in
contrast only 1 of 4 patients lacking RMEL3 expression showed no
lymph vascular invasion (p=0.002). Additionally, RMEL3
expression positively correlates (p=0.001) with improved patient
status, as 6 of 10 patients in the group with detectable expression
lived without the disease in contrast to none of 12 over the same
period of follow up in the group lacking RMEL3 expression.
Survival curves calculated using Kaplan-Meier method show that
lack of RMEL3 expression in the tumor correlates with poor
survival rates, with most deaths occurring within 2.2 years of
follow up, an interval in which all ten patients with detectable
expression were still alive (Figure 3C).
Structure, conservation, and predicted products for the
three novel melanoma-restricted genes
The three validated genes are composed of multiple exons.
RMEL1 (Figure 4A) spans over a region of 19,212 bp on
chromosome 2q12.2 and includes six exons supported by EST
data, four of which are constant and two alternatively spliced.
Although the UniGene cluster of this gene is composed of 16
expressed sequences, 1 derived from polyadenylated mRNA (long
cDNA) and 15 ESTs, the UCSC Genome Browser shows the same
sequences as the UniGene cluster plus 4 ESTs, totalizing 20
expressed sequences, derived from four different melanoma
libraries, mapping to this locus. RMEL2 spans 7,545 bp and is
composed of three exons mapped to chromosome 1q25.3 with no
evidence of alternative transcripts (Figure 5A). Also for this gene,
the UCSC Genome Browser indicates the existence of additional
expressed sequences (6 cDNAs and 11 ESTs) mapping to this locus
in comparison to the UniGene cluster (12 ESTs). The third gene,
RMEL3, maps to an extension of 138,365 bp on the chromosome
region 5q11.2 and is organized in four exons separated by very
large introns. There are only three ESTs representing this gene
according to the UniGene and UCSC Genome Browser as well.
Curiously, an intron-less gene annotated as ACTBL2 maps to the
longest intron of RMEL3 (Figure 6A).
All three genes show very low sequence conservation even
within mammals. According to BLAT and VISTA alignments, the
three complete genes are well conserved only throughout the
various primate genomes (Figures 4-6, B). They are partially
conserved in dog and horse, and only RMEL2 has conserved
portions of exonic sequences (exon 3) in mouse and rat (Figure 5B).
The CPC software predicted that these genes have no coding
potential, but RMEL2 has been classified as a weak non-coding
sequence. They have several stop codons in all possible frames, but
some short ORFs can be detected in their sequences (Figures S1,
S2, S3). We searched the sequences for the presence of ORFs with
both the canonical AUG-start codon and alternative non-AUG
codons, since there is an increasing number of reports showing the
use of alternative translation initiation sites in mammals [15]. For
RMEL1, the longest ORF, which is conserved across the various
primates, is an AUG-starting ORF encoding a 49 aa long
polypeptide (Figure 4C). However, assuming the use of alternative
start codons, this gene has a longer ORF encoding a polypeptide
of 91 aa residues. This is not a conserved ORF and it may have
arisen recently from a single base pair alteration that creates a
UGG codon for tryptophan, in place of the UGA-termination
codon found in other primate genomes (Figure S4). For RMEL2,
the longest putative ORF encodes a polypeptide chain of 98 aa
residues, whose sequence is conserved within primates. Interest-
ingly, the corresponding ORF in M. mulatta predicts a polypeptide
with an additional 36 aa N-terminal (Figure 5C). For RMEL3, the
longest putative ORF is an AUG-starting ORF that encodes a 45
aa long polypeptide conserved in the other three primates
(Figures 6C and Figure S3).
We also considered the possibility that the genes could represent
non-coding RNAs. We have not found any matches between these
RNA sequences and previously characterized or predicted non-
Figure 1. Validation by real-time RT-PCR of the melanoma/melanocyte-restricted expression of RMEL1, 2 and 3. Relative expression was
calculated according to 2
2DDCT method, using TBP (Tata-box binding protein) as endogenous control and the sample displaying the lowest
normalized Ct as reference. The tissue panel included normal melanocytes (NM), melanoma cell lines (melanoma), including those harboring the
activating BRAF V600E mutation (*), wild type BRAF (not marked), or with mutation status not determined (ND); and various cell lines and tissues of
non-melanocytic origin (non-melanoma), including primary skin fibroblasts, HeLa, HL-60, Jurkat cells, peripheral blood mononuclear cells (PBMC), and
necropsy samples from spleen, brain, esophagus, liver, intestine, skeletal muscle, kidney, normal bladder (NB), bladder tumor (BT), normal prostate
(NP), prostate tumor (PT), normal glia (NG), gliobastoma (GBM).
doi:10.1371/journal.pone.0013510.g001
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However, RNA secondary structures were predicted from their
sequences, according to the RNAZ software, which predicts RNA
functional structure based on both, structural conservation and
thermodynamic stability. For each RMEL gene, the RNA
structure prediction was based on multiple alignments of five
primate sequences (Homo sapiens, Pan troglodytes, Pongo pygmaeus,
Macaca mulatta and Callithrix jacchus). The software provides an
overall RNA-class probability. If this probability is .0.5 (the closer to
1.0 this value is, the more confident is the prediction), the
alignment is classified as ‘‘functional RNA’’, indicating that the
sequence is from a potential RNA element in ncRNAs or a cis-
regulatory element of mRNAs. For RMEL1 (Figure 4C) and
RMEL3 (Figure 6C), five and three RNA structure predictions
with very high probability (RNA-class probability .0.95) were
generated, whereas for RMEL2 (Figure 5D) there was only one
prediction and with lower probability (RNA-class probability =0.87),
compatible with the prediction that RMEL2 is most likely a protein
coding gene.
Discussion
We developed a pipeline tool for EST data mining that is simple
but effective in identifying genes displaying tissue-specific expres-
sion, according to our validation results. Most of the 38 UniGene
clusters initially indicated by the analysis were indeed composed
only of sequences derived from melanoma libraries and we
validated the expression profile for three genes selected for
experimental validation from the final list of 29 clusters, indicating
that other candidates from the list should be validated as well in
the future. Due to the high stringency of our search, ESTs for
genes traditionally known as melanocyte/melanoma-specific
genes, such as TYR (Hs.503555), DCT (Hs.301865), MLANA
(Hs.154069), and SILV (Hs.95972), were not selected because they
also match entries of other tissue datasets. Although we might have
missed relevant genes with differential expression, we selected
genes with highly specific expression. The use of such genes could
improve the detection of early metastasis and help predict patient
outcome. Since the expression of RMEL1 and RMEL2 is very
specific to melanocyte/melanoma cells and their expression is
preserved in great number of tumor samples, they are both
valuable candidates, as molecular markers, for example to detect
circulating tumor cells in the blood of melanoma patients. Given
the correlation with clinical aspects, RMEL2 and RMEL3
expression might be valuable as prognostic markers and
assessment of treatment response.
Most of the genes identified here seem to encode short peptides,
and five out of the seven deduced proteins with characterized
structural motifs contain nucleic acid-binding domains. Four of the
deduced proteins match regions of the ORF2 of the retro-
transposon element LINE-1. These elements, representing 17% of
the human genome, are not frequently expressed in adult somatic
cells, and evidence suggests that their transcripts may have
oncogenic roles (for review [16]). It is also interesting to point out
that almost 35% of the genes identified in this study have no
predicted coding potential and might represent non-coding RNAs.
Of the three genes validated, RMEL1 seems to be a novel
melanocytic lineage-specific gene with significant up-regulation in
primary and metastatic tumors. Whether it plays a role in
melanocyte differentiation and melanoma progression, like other
melanocyte-specific genes such as MITF [17,18], is an interesting
matter for future studies. Of note, RMEL1 expression was far more
restricted to melanocytic cells than that observed for canonical
melanocyte-specific genes.
RMEL2 was the gene most strictly associated to malignancy in
melanoma and possibly glioblastoma, since it is not expressed in
normal melanocytes or glia and is barely detected in nevi, yet it is
up-regulated in ,50% of the melanomas (and 1 of 3 glioblasto-
mas). RMEL2 maps to 1q25.3, a region (1q23.3–q25.3) frequently
amplified in melanomas [19]. Therefore, it is possible that RMEL2
is up-regulated in melanoma by means of genomic amplification.
Future functional studies will be required to discern its disease
significance from merely a bystander in the process.
RMEL3 shows an intriguing expression profile, suggestive of a
possible role for this gene in nevi and as a tumor or metastasis
suppressor. Although melanocytic nevi are benign lesions that
rarely progress to malignant melanoma, they are altered in
relation to normal melanocytes and frequently exhibit the
oncogenic activating BRAF mutation V600E [20,21]. It has been
proposed that nevi cells suffer an initial proliferation step, and are
growth arrested by an oncogene-induced senescence mechanism
[22]. Recent work identified several genes required for the
BRAFV600E-induced senescence and showed that in the context
of BRAF mutation, expression loss of one of them, IGFBP7,i s
critical in promoting the progression to melanoma [23]. RMEL3
profile resembles that of IGFBP7 in some ways, since its expression
is not detected in melanocytes while it is up-regulated in nevi and
absent from most metastases and about half of the primary tumors.
Also, mapping of the conserved gene ACTBL2 to an RMEL3
intron may represent a meaningful regulatory interrelationship
with reflex in the actin cytoskeleton dynamics and cell migration.
Future research to uncover the function of this gene may reveal
novel insights into the molecular alterations of melanocytic nevi
implicated in melanoma progression.
Curiously, the three RMEL genes were predicted as having no
coding potential. Other genes previously classified as non-coding
RNA genes have been shown to encode short functional peptides
[24,25]. Of the three genes analyzed, RMEL2 has the highest
probability to encode a protein, and although the other two had
AUG-starting ORFs encoding fewer than 50 amino acid residues,
a longer ORF starting at an alternative codon was detected for
RMEL1. This ORF (encoding 91 aa) is present only in the human
sequence and may have originated from an ancestral non-coding
sequence, as recently proposed in an interesting work that provides
evidence for the origin of three novel human-specific ORFs from
ancestral non-coding sequences [26]. Besides the possibility of
these genes encoding polypeptides that are primate- or even
human-specific, they are also candidates for encoding primate-
specific functional non-coding RNAs. However, more conclusive
evidence regarding evolutionary conservation of these genes will
only be possible after the actual encoded products are defined.
Figure 2. Expression profiles of RMEL1, 2 and 3 during melanoma progression. Relative expression was calculated according to 2
2DDCT
method, using TBP (Tata-box binding protein) as endogenous control and the mean value of the normalized Cts of all nevi samples as reference.
cDNA samples derived from keratynocytes (Ker), nevi (N), primary melanoma tumors (P) and melanoma metastasis (M), from different patients
(distinguished with a number following the letter N, P or M) were analyzed by Real-Time PCR. Statistical analyses were performed using ANOVA (after
loge transformation of the data), for RMEL1 and RMEL2, or the Mann–Whitney test for RMEL3. Metastatic samples numbered 79, 81 and 105 are from
lymph node metastasis; 50, 80, 93, 95, 96, 108, 113 and 127 from skin metastasis; 106 from lung metastasis and 82, 83, 116 and 129 from visceral
metastasis.
doi:10.1371/journal.pone.0013510.g002
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PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13510Large scale studies have demonstrated that most regions of
eukaryotic genomes are transcribed as non-coding RNAs and an
increasing numberof thesemolecules have been implicatedinmany
regulatory processes [27,28]. Notably, several non-coding regula-
tory RNAs, microRNAs (miRNAs), were recently discovered as
involved in critical steps of the tumorigenesis and metastasis
cascades, in several types of cancer including melanoma [29,30,31].
According to the miRBase, there are no annotated or predicted
miRNAs mapping to the RMEL genomic regions. Thus, one
possibility is that RMELs encode miRNAs not previously identified
due to their highly restricted tissue expression pattern. Another
possibility is that they belong to the class of long non-coding RNAs.
These types of RNAs are very heterogeneous, and novel long non-
coding RNAs are difficult to identify based on sequence analysis
Figure 4. Structural organization, phylogenetic conservation, and predicted products for RMEL1 (Hs.295012). (A) Genome context of
the gene. The longest cDNA (BC038566) suggests a four-exon gene and ESTs (BE386026, BU156136 and BQ217207) suggest two more exons (shaded
boxes). Numbers indicate intron and exon lengths in nucleotides. (B) VISTA plot displaying the conservation of the gene in nine species. The upper
and lower limits of the box representing each species correspond, respectively, to 100 and 50% of sequence identity. (C) Multiple alignment of the
deduced amino acid sequences of the RMEL1 longest AUG-starting ORF of several primate species. (for all species, ORFs were deduced from putative
transcribed sequences obtained by alignments of the human cDNA BC038566 against the genomic sequences). (D) Diagram of RNA secondary
structures predicted by RNAz software. Rule indicates RNA length; pointed blue bars indicate segments predicted to form hairpin structures, and the
numbers indicate the RNA-class probability (P), considered significant when greater than 0.5. Predicted RNA secondary structures for two of the
segments (indicated by arrow heads) are shown.
doi:10.1371/journal.pone.0013510.g004
Figure 3. Kaplan-Meier estimates of cumulative survival for melanoma patients according to the expression of RMEL1 (A), RMEL2 (B)
and RMEL3 (C). Patients were divided into two groups according to expression levels, classified as lower or equal and higher than the maximal
detected in nevi, for RMEL1, and as detected (D) and non-detected (ND), for RMEL2 and RMEL3. The Kaplan-Meier survival curves were calculated
using the SPSS Statistics version 18.0 from SPSS (IBM Company).
doi:10.1371/journal.pone.0013510.g003
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phylogenetic scale [28,32]. Indeed, the three genes identified here
are significantly conserved throughout primate genomes only.
Interestingly, besides miRNAs, several short and long non-coding
RNAs have also been implicated in cancer development and
described as cancer markers [28]. An interesting example is DD3/
PCA3, a prostate cancer-specific RNA showing low conservation in
non-primate mammals [33,34]. Although no role for this gene in
prostate cancer has been proposed, detection of DD3 RNA in body
fluids proved useful for predicting prognosis [35,36]. No studies
concerning diagnostic applications of non-coding RNAs are
available for melanoma. although there is great expectation towards
this end (see[31]).
In summary, we here presented a new strategy for extracting
valuable information from expressed sequence databases, and
generated a list of 28 potential genes, represented by 29 UniGene
clusters, with validated probability of being involved in melanoma.
To our knowledge, the three validated genes shown here were
found to have the most restricted expression patterns ever seen for
melanoma and we presume that future functional studies of these
genes will shed new light on melanocyte and melanoma biology.
The small scale correlative study of gene expression and clinical
data shown here lead us to suggest that especially RMEL3 is likely
to play an active role as a tumor and metastasis suppressor, but
also RMEL2 may function to impose constraints to the initial
development of the primary tumor and perhaps has a role in
Figure 5. Structural organization, phylogenetic conservation, and predicted products for RMEL2 (Hs.518391). (A) Genome context of
the gene. The numbers indicate the intron and exon lengths in nucleotides. The region in blue represents the longest ORF found, spanning 294 bp
and encoding 98 aa. (B) VISTA plot displaying the conservation of the gene in nine species. The upper and lower limits of the box representing each
species correspond, respectively, to 100 and 50% of sequence identity. (C) Multiple alignment with ClustalW of the deduced amino acid sequences
for the longest AUG-starting ORF of RMEL2 in several primate species (for all species, ORFs were deduced from putative transcribed sequences
obtained by alignments of the human cDNA BC063324 against the genomic sequences). (D) Diagram showing an RNA secondary structure predicted
by RNAz software. Rule indicates RNA length; pointed blue bar indicates a segment predicted to form the hairpin structure shown, and the number is
the RNA-class probability (P) of the prediction, considered significant when greater than 0.5.
doi:10.1371/journal.pone.0013510.g005
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worthwhile to assess the relevance of RMEL2 expression as a
marker to predict disease outcome in lymph node-negative
patients and RMEL3 as a general marker of melanoma patient
outcome. For RMEL1 we suggest a possible involvement in
differentiation/pigmentation since it is expressed in normal
Figure 6. Structural organization, phylogenetic conservation, and predicted products for RMEL3 (Hs.559350). (A) Genome context of
the gene. ESTs available (BQ420825, CR746619 and BU161974) for the gene suggest the occurrence of four exons separated by large introns. In the
opposite strand of the first intron there is an intron-less actin-like gene (ACTLB2). The numbers indicate the intron and exon lengths in nucleotides. (B)
VISTA plot displaying the conservation of the gene in nine species. The upper and lower limits of the box representing each species correspond,
respectively, to 100 and 50% of sequence identity. (C) Multiple alignment with ClustalW of the deduced amino acid sequences for the longest ORF,
which is a primate-conserved AUG-starting ORF, in several primate species (for all species, ORFs were deduced from putative transcribed sequences
obtained by alignments of the human EST BQ420825 against the genomic sequences). (D) Diagram of RNA secondary structures predicted by RNAz
software. Rule indicates RNA length; pointed blue bars indicate segments predicted to form the hairpin structures shown, and the numbers indicate
the RNA-class probability (P) of the prediction, considered significant when greater than 0.5.
doi:10.1371/journal.pone.0013510.g006
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color in melanoma patients. Concluding, we expect that the data
presented here offers promising new targets for future validation in
large clinical studies as diagnosis markers or for development of
therapeutic strategies.
Materials and Methods
Software development and implementation
Using Perl scripts all the reports of the dbEST database were
downloaded and locally inserted into a MySQL database. All
ESTs corresponding to Homo sapiens were selected and then, a
human tissue source list were created collecting all the terms added
to six fields (Cell line, Cell type, Description, Lab name, Tissue
type and Title) of the dbEST submission files (606 terms). The
human UniGene reports were also downloaded as text files and
then were pre-processed to eliminate unnecessary fields; the
remaining fields were indexed, using ‘MySQL’. The process of
identification of tissue-specific genes starts by selecting a keyword
from the list of tissue source terms. The selected term is the input
argument for the search engine. The MySQL Database
Management System separates the ESTs in two groups: a) ESTs
whose tissue source matches the selected keyword and b) ESTs
whose tissue source does not match the selected keyword. After the
separation, each EST is associated to its corresponding UniGene
cluster. Then, the search engine compare the two lists of clusters
generated in the first step in order to identify clusters formed only
by ESTs belonging to libraries matching the keyword. Based on
these criteria we detect only the ESTs that are tissue-specific.
The implementation of the methodology described above was
done using Perl scripts, which basically trigger SQL commands to
the MySQL database, to perform the searches. The results of the
SQL commands are then stored by the Perl script for further
comparison of clusters lists. The results found by the Perl script are
then sent to a PHP script, for correct formatting and HTML
presentation. This PHP script is also responsible for controlling the
HTML form that gets the selected keyword and sends it to the Perl
script. All the developed scripts and the MySQL database are
running into a GNU/Linux server. The tool named EST2TSE
(EST to Tissue Specific Expression) is available at http://www.
prometheus.fmrp.usp.br/EST2TSE.
Selection of melanoma-specific genes (EST clusters)
Using the methodology described above and the dbEST [37]
and the Unigene data as of January 2007, we were able to separate
the EST reports into two groups: (i) ESTs whose tissue origin was
melanoma (Melanoma group: 129,906 sequences); and (ii) ESTs
derived from any tissue except melanoma (Non-melanoma group:
7,895,596 sequences). Melanoma sequences were derived from 12
melanoma libraries, the largest one containing 41,936 sequences
and the smallest 19 sequences. We next associated the melanoma
and non-melanoma ESTs to UniGene clusters and compared the
two lists of clusters in order to identify clusters formed by ESTs
found in the melanoma group only.
Cell culture
The following human cells were used: primary foreskin
melanocytes (FM305 and FM308); melanoma cell lines harboring
the BRAF V600E/I mutation (*), wild type for this allele or with
mutation status not determined (ND); RGP (radial growth phase)
lines WM35*and WM1552*; VGP (vertical growth phase) lines
WM278*, WM793*, and WM902*; metastatic lines WM9 (ND),
WM852 (ND), 1205Lu*, WM1617*, SK-Mel-19*, SK-Mel-28*,
SK-Mel-29*, SK-Mel-94*, UACC-62*, SK-Mel-103, SK-Mel-
147, SK-Mel-173, and UACC-257; cervical carcinoma HeLa
cells; Jurkat T cell leukemia; HL-60 promyelocytic leukemia cells;
and primary skin fibroblasts.
WM melanoma cell lines were maintained as previously
described [38]. All the other melanoma cells, the HeLa cells,
and the primary cultured fibroblasts were maintained in Dulbeco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 50 U/mL penicillin, and 50 mg/mL strepto-
mycin. The normal melanocytes were isolated from neonatal
foreskin and maintained as previously described [39]. Jurkat and
HL-60 were cultured in RPMI medium supplemented with 10%
FBS, 50 U/mL penicillin, and 50 mg/mL streptomycin. We
periodically monitored cell morphology and observed no changes
in the cell lines. All cells were frequently checked for mycoplasm
contamination by DAPI staining.
Ethics Statement
The study protocol for the collection of all non-melanoma
tumor and normal tissue samples was approved by the Ethics
Committee of the Hospital das Clı ´nicas da Faculdade de Medicina
de Ribeira ˜o Preto, Universidade de Sa ˜o Paulo (# 7645/1999 and
7645/2005), and written informed consent was obtained from
each patient. Nevi and melanoma biopsy samples were obtained
from patients at the Hospital do Ca ˆncer AC Camargo, Sa ˜o Paulo,
with written informed consent provided by all patients, and
according to protocols approved by the Ethics Committee of the
Hospital do Ca ˆncer AC Camargo (# 560/03 and 567/04).
Processing of the biopsy and necropsy samples
The non-melanoma samples were processed as previously
described [40]. In the case of the nevi and melanoma samples,
after biopsy, all of them were split in two fragments: one was
maintained in RNAlater (Ambion, Austin, TX) and the second
was processed for hematoxylin-eosin staining and pathologic
analysis. Fragments kept on RNAlater were processed when
histopathological diagnosis was confirmed. All tissue fragments
were microdissected for maximal exclusion of non-melanocytic
cells.
RNA extraction and real time RT-PCR
Total RNA was isolated from all human cell lines, non-
melanoma biopsy, and necropsy samples using TRIzol (Invitro-
gen, Carlsbad, CA) according to manufacturer’s instructions.
RNA integrity was checked by formaldehyde-agarose gel electro-
phoresis for all samples and then 1 mg of DNase-treated RNA
(DNA-free kit, Ambion, Austin,TX) was converted into cDNA
using the High-Capacity cDNA Reverse Transcription kit
(Applied Biosystems, Foster City, CA).
Total RNA from nevi and melanoma biopsies was isolated using
the RNeasy Midi kit (Qiagen, Hilden, Germany) and then
submitted to a mRNA amplification as protocol previously
described [41], with modifications. Briefly, 3 mg of total RNA
were used for first and subsequent second strand cDNA synthesis
using the ImProm-II reverse transcription system (Promega,
Madison, WI). Ds-cDNA was cleaned up by phenol/chloro-
phorm/isoamyl alcohol extraction and ammonium acetate
precipitation. Amplified RNA (aRNA) was obtained by in vitro
transcription from 10 ml of ds-cDNA using the RiboMAX system
(Promega, Madison, WI) and subsequent purification using
TRIzol (Invitrogen, Carlsbad, CA). For the final cDNA synthesis,
1 mg of aRNA was converted to cDNA using the RT Improm II
system (Promega, Madison, WI).
Equal amounts of each cDNA were analyzed by real-time PCR
using specific primers (400 nM) and SYBR Green PCR Power
Novel Melanoma-Specific Genes
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Sequence Detection System (Applied Biosystems, Foster City, CA).
Each sample was measured in duplicate. All primer sequences are
listed in Table S4. To avoid amplification of undesirable genomic
DNA, we designed primer pairs flanking introns. All primers were
submitted to efficiency tests using serial dilutions of mixture of
cDNAs from five melanoma cell lines (WM35, WM793, WM9,
1205, and WM1617). Only primer pairs presenting efficiency in
the range of 90–110% were used. Cycle threshold (Ct) was
converted to relative expression according to the 2
2DDCT method,
using TBP (TATA-box binding protein) as endogenous control.
For data analysis, in the case of cell lines and non-melanoma
tissues, sample displaying the lowest normalized Ct was taken as
reference, and in the case of melanoma tissues, reference was the
mean value of the normalized Cts of all nevi samples. Statistic
significance (P,0.05) of the differences in the expression levels was
determined using ANOVA (SAS software, version 9.0), after loge
transformation of the data, for the genes RMEL1 and RMEL2, or
the Mann–Whitney test (SigmaPlot software) for RMEL3.
Statistical analysis
Statistical significance (P,0.05) of the differences in the
expression levels of RMEL genes among the sample groups (nevi,
primary tumors and metastasis) was determined using ANOVA
(SAS software, version 9.0), after loge transformation of the data,
for the genes RMEL1 and RMEL2, or the Mann–Whitney test
(SigmaPlot software) for RMEL3. The correlations between the
gene expression and clinicopathologic variableswereevaluatedby
the Likelihood Ratio Chi-square test, using the software JMP
version 6.0.0 from SAS Institute Inc. Patient survival curves were
calculated by the Kaplan-Meier method, with the statistical
significance evaluated by the Breslow (Generalized Wilcoxon)
test, using the SPSS Statistics version 18.0 from SPSS (IBM
Company).
Sequence analysis
For analyses of coding potential and definition of the deduced
ORFs we used the software Coding Potential Calculator (CPC)
[42] and the software Translator [43]. We used default
parameters to perform the analyses and accepted the CPC pre-
defined decision scores. We used the Translation Map tool [44]
for translation maps. Before the ORF analyses, all human cDNA
sequences were aligned to the human genome and those
presenting sequence mismatches were corrected on the basis of
the genomic sequence. Human genomic sequences of interest,
obtained from the UCSC Genome Browser [45], were aligned to
other genomes using the GenomeVISTA tool [46], generating a
phylogenetic conservation plot. RNA secondary structure of
RMEL1, RMEL2,a n dRMEL3 was predicted using the RNAz
software [47,48]. The putative cDNA sequence of each gene of
interest from four primate species was deduced by alignments
with the human cDNA sequences (RMEL1: BC038566, RMEL2:
BC063624 and RMEL3: BQ420825) using the BLAT tool
(UCSC Genome Browser). The sequences were then provided
to Clustal W and the multiple alignments generated were used as
input for the RNAz software. Putative transcription factor
binding sites in gene promoters were predicted using the AliBaBa
2.1 tool [49] that uses the TF (transcription factor) binding site
database TRANSFAC. Putative promoter regions of all genes
represented by cDNA sequences longer than 700 bp were
included in our analysis. Genomic regions mapping at 2.0 kb
upstream of the cDNA sequence were obtained with the UCSC
GenomeBrowser and submitted to AliBaBa 2.1, generating a list
of TF binding sites for each promoter. Using a locally developed
script, all lists were compared to each other and a single list
displaying the frequency of all TF elements detected for each
promoter was generated.
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Table S1 Comparison of EST2TSE with other tools for tissue
specific gene selection from EST databank.
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